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test; bioMérieux). DNA was extracted
from cultures grown on agar plates
and amplified following a previously
described protocol (1). The following
oligonucleotide primer sequences
were used: luk-PV1, 5′-ATCATTAG-
GTAAAATGTCTGGACATGATC-
CA-3′; luk-PV2, 5′-GCATCAAGTG-
TAT T G G ATA G C A A A A G C - 3 ′ .
Polymerase chain reaction products
were sequenced commercially and
submitted to GenBank (accession no.
AY508231).
This case is the first in Singapore
of community-acquired pneumonia
caused by S. aureus in which an
attempt was made to detect Panton-
Valentine leukocidin genes. Given
that the patient had not traveled, she
likely acquired the lethal strain of
Panton-Valentine leukocidin–positive
S. aureus locally. This idea is further
supported by a recent study which
reported that the Panton-Valentine
leukocidin gene is found worldwide,
albeit in community-acquired strains
of methicillin-resistant S. aureus (3).
The incidence of severe communi-
ty-acquired pneumonia attributable to
Panton-Valentine leukocidin–positive
S. aureus is unknown in many parts of
the world. With one exception (4),
cases of Panton-Valentine leuko-
cidin–positive S. aureus causing com-
munity-acquired pneumonia have
been reported sporadically only from
European countries and the United
States (1,2,5–8). These results may be
attributable to the lack of recognition
rather than to the rarity of the condi-
tion. A previous report showed that
7.6% of cases of severe community-
acquired pneumonia in patients
requiring ventilatory support in
Singapore were caused by S. aureus
(9), and a large proportion of these
would fit the clinical syndrome
described by Gillet et al. (2). Given
the ease of transmitting the infection
to close contacts (7,10), with the real
possibility of a consequent outbreak
(10), Panton-Valentine leukocidin
testing should be conducted on  S.
aureus strains isolated from all
patients with community-acquired
necrotizing pneumonia and furuncu-
losis for infection control purposes.
Implementing standard hospital
methicillin-resistant S. aureus meas-
ures resulted in control of the out-
break described by Boubaker et al.
(10). This measure seems especially
relevant given the dismal prognosis
offered by conventional therapy in
which the death rate of patients with
necrotizing pneumonia may reach
75% (2). Further research on the epi-
demiology, optimal therapy, and pre-
vention of this infection is needed.
Li-Yang Hsu,* Tse-Hsien Koh,*
Devanand Anantham,*
Asok Kurup,* 
Kenneth Ping Wah Chan,* 
and Ban-Hock Tan*
*Singapore General Hospital, Singapore
References
1. Lina G, Piémont Y, Godail-Gamot F, Bes
M, Peter MO, Gauduchon V, et al.
Involvement of Panton-Valentine leuko-
cidin–producing Staphylococcus aureus in
primary skin infections and pneumonia.
Clin Infect Dis. 1999;29:1128–32.
2. Gillet Y, Issartel B, Vanhems P, Fournet JC,
Lina G, Bes M, et al. Association between
Staphylococcus aureus strains carrying
gene for Panton-Valentine leukocidin and
highly lethal necrotising pneumonia in
young immunocompetent patients. Lancet.
2002; 359:753–9. 
3. Vandenesch F, Naimi T, Enright MC, Lina
G, Nimmo GR, Heffernan H, et al.
Community-acquired methicillin-resistant
Staphylococcus aureus carrying Panton-
Valentine leukocidin genes: worldwide
emergence. Emerg Infect Dis. 2003;8:
978–84.
4. Miyashita T, Shimamoto Y, Nishiya H,
Koshibu Y, Sugiyama H, Ono Y, et al.
Destructive pulmonary embolism in a
patient with community-acquired staphylo-
coccal bacteremia. J Infect Chemother.
2002;8:99–102.
5. Boussard V, Parrot A, Mayaud C, Wislez
M, Antoine M, Picard C, et al. Life-threat-
ening hemoptysis in adults with communi-
ty-acquired pneumonia due to Panton-
Valentine leukocidin–secreting Staphylo-
coccus aureus. Intensive Care Med.
2003;29:1840–3.
6. Klein JL, Petrovic Z, Treacher D,
Edgeworth J. Severe community-acquired
pneumonia caused by Panton-Valentine
leukocidin–positive Staphylococcus
aureus: first reported case in the United
Kingdom. Intensive Care Med.
2003;29:1399. 
7. Osterlund A, Kahlmeter G, Bieber L,
Runehagen A, Breider JM. Intrafamilial
spread of highly virulent Staphylococcus
aureus strains carrying the gene for Panton-
Valentine leukocidin. Scand J Infect Dis.
2002;34:763–4. 
8. Naimi TS, LeDell KH, Como-Sabetti K,
Borchardt SM, Boxrud DJ, Etienne J, et al.
Comparison of community- and health
care-associated methicillin-resistant
Staphylococcus aureus infection. JAMA.
2003;290:2976–84. 
9. Tan YK, Khoo KL, Chin SP, Ong YY.
Aetiology and outcome of severe commu-
nity-acquired pneumonia in Singapore. Eur
Respir J. 1998;12:113–5.
10. Boubaker K, Diebold P, Blanc DS,
Vandenesch F, Praz G, Dupuis G, et al.
Panton-Valentine leukocidin and staphylo-
coccal skin infections in schoolchildren.
Emerg Infect Dis. 2004;10:121–4.
Address for correspondence: Li-Yang Hsu,
Infectious Disease Unit, Department of Internal
Medicine, Singapore General Hospital, Outram






To the Editor: Balamuthia man-
drillaris, a free-living soil ameba, can
cause granulomatous amebic
encephalitis as well as nasopharyn-
geal, cutaneous, and disseminated
infections in humans, nonhuman pri-
mates, and other animals. Appro-
ximately 100 published and unpub-
lished cases of Balamuthia amebic
encephalitis (BAE) have been report-
ed; most were fatal. Diagnosis of
BAE is usually made at autopsy, and
rarely by biopsy, in part because the
amebas can be overlooked in
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histopathologic preparations. In rec-
ognizing BAE as a type of encephali-
tis that might otherwise be undiag-
nosed, the California Encephalitis
Project (1) has been screening select-
ed serum samples from patients with
encephalitis for evidence of antibod-
ies to Balamuthia. 
We describe cases of BAE in
California and compare data with
national data collected on Balamuthia
infections since the discovery of the
organism in 1990. Since 1998, serum
and other samples (cerebrospinal fluid
[CSF], throat and rectal swabs, brain
tissue) from patients with encephalitis
have been submitted to the California
Encephalitis Project by participating
physicians throughout California. The
goal of the California Encephalitis
Project is to provide enhanced diag-
nostic testing for etiologic agents of
encephalitis through an intensive test-
ing algorithm. The case definition of
encephalitis is encephalopathy, plus
one or more of the following: fever,
seizures, focal neurologic findings,
CSF pleocytosis, or electroencephalo-
graphic or neuroimaging findings
consistent with encephalitis (1).
Persons with HIV/AIDS, severely
immunocompromised patients, and
patients <6 months of age are exclud-
ed from the project.
Serum samples were selected for
screening for Balamuthia antibodies
if the patient had clinical or laborato-
ry features suggestive of Balamuthia
encephalitis (elevated CSF protein
and leukocyte counts or compatible
findings on neuroimaging) and a his-
tory of outdoor occupational (agricul-
ture or construction work) or recre-
ational (camping or swimming) activ-
ities during which they may have been
exposed to pathogenic or opportunis-
tic free-living amebas. During the
study, 215 (approximately 25%) of
the >850 serum samples collected in
California were tested for Balamuthia
infection by indirect immunofluores-
cence assay (2). Testing was conduct-
ed on acute-phase serum and a follow-
up sample, when available. Serum
samples were tested at dilutions from
1:2 to 1:4,096. Positive and negative
control samples were run in parallel,
with titers from 1:128 to 1:256 for the
former and negative to 1:32 for the
latter. Serum samples from patients
with Balamuthia encephalitis did not
cross-react with Acanthamoeba or
Naegleria, two other amebas associat-
ed with amebic encephalitis (3). 
Three (1.4%) of 215 samples test-
ed were positive for antibodies to
Balamuthia with titers of 1:128,
1:128, and 1:256.  In the course of the
study period, serum samples from
four additional persons, including
serum from one person who had been
diagnosed by the Centers for Disease
Control and Prevention (CDC), who
were not part of California
Encephalitis Project were positive.
The diagnosis of Balamuthia
encephalitis was confirmed histologi-
cally or by indirect immunofluores-
cence staining of tissue sections in all
seven cases; in one case amebas also
were isolated in culture from necrotic
brain tissue at autopsy (4). All patients
were immunocompetent and of
Hispanic American ethnicity, and all
died. Case-patients included two
adults and three children who were
native Californians, a child who had
arrived from Mexico the previous
year, and a child who was a native of
Texas who had been diagnosed by the
California Department of Health
Services (5). The observation that all
were of Hispanic American ethnicity
prompted a search through CDC’s
records (N = 104) to confirm the eth-
nicity of BAE patients throughout the
world (G.S. Visvesvara, unpub. data).
Patients were considered to be of
Hispanic American ethnicity if they
were identified as such in case histo-
ries or if they had traditional Hispanic
surnames. Specific confirmation of
ethnicity was not available in the
CDC records, and reliance on sur-
names to determine ethnicity might be
a source of error; some Hispanic
American persons may have sur-
names that are not considered to be
ethnically Hispanic, and vice versa.
According to the records, approxi-
mately 50% of the 50 North American
patients, which were confirmed by
direct immunofluorescence, histo-
pathology, or both, were Hispanic
American. Thirty-six percent of all
the BAE cases occurred in Latin
America. Eleven cases have occurred
in California since the early 1990s,
including those described above, and
all but two were fatal (6). Eight (73%)
of these 11 cases occurred in Hispanic
Americans. 
BAE is not an insignificant disease
in California, with 11 cases and 9
deaths reported in the state in the last
decade. By comparison, five deaths
from indigenous rabies have been
reported in the state since approxi-
mately 1990 (7). Furthermore, BAE is
likely underdiagnosed because of
unfamiliarity with appearance of ame-
bas in tissue sections and nonspecific
symptoms. Unless there is a high
degree of suspicion, it is unlikely that
testing for Balamuthia would be con-
ducted. Most cases are diagnosed on
autopsy, which is often not allowed by
families. Also, BAE develops in a dis-
proportionate number of Hispanic
Americans. Hispanic Americans make
up 12.5% of the U. S. population
(United States Census Bureau statis-
tics for 2000) but represent approxi-
mately 50% of the cases of BAE. In
California, where Hispanic Americans
make up 32% of the state’s popula-
tion, they have 73% of BAE cases (p
= 0.001, Fisher exact test). In the
California Encephalitis Project,
Hispanic Americans accounted for
approximately 25% of all cases of
encephalitis, 26% of serum samples
examined for Balamuthia antibody,
and 21% of cases of viral and bacteri-
al encephalitis, but all BAE patients
(n = 3) were in Hispanic Americans
(Figure). 
Balamuthia lives in soil (4) and
can enter through the respiratory tract
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or breaks in the skin. Hispanic
Americans may be more likely to
reside in agrarian settings with
increased exposure to soil and oppor-
tunities for contamination of cuts and
other injuries. Whether caused by
environmental factors, genetic predis-
position, access to medical care, or
other socioeconomic factors and pres-
sures, the reasons for the higher inci-
dence of BAE in Hispanic Americans
warrant further study. 
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To the Editor: Since its emer-
gence early in 2003, the epidemic of
severe acute respiratory syndrome
(SARS) has been characterized by its
rapid spread among healthcare work-
ers. On August 14, 2003, the World
Health Organization (WHO) issued an
alert concerning SARS and recom-
mended a staged approach to surveil-
lance (1). Because occupational trans-
mission has been a feature of the
SARS outbreak, WHO recommends
surveillance for clusters of alert cases
among healthcare workers in low-risk
areas (i.e., cases not reported, only
imported cases reported, or local
cases with limited transmission poten-
tial reported). A SARS alert is identi-
fied when two or more healthcare
workers in the same healthcare unit
meet the clinical case definition of
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Figure. The graph compares Hispanic American populations and Hispanic American
Balamuthia amebic encephalitis (BAE) cases in the United States, California, and those
samples tested for Balamuthia antibody in the California Encephalitis Project (CEP). In
each of the three groups, the percentage of Hispanic Americans in the population is com-
pared to the percentage of BAE cases in Hispanic Americans.
